Announcements Trials
Browse Landscape

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thrombosis 1Polycythemia Vera 1Polycythemia 1Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Phlebotomy × Clear all
NCT00507702 2019-04-18

Identification of Key Blood Molecular Markers for Immunotherapy

Stanford University

Terminated
191 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡